Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P0DMN0

UPID:
ST1A4_HUMAN

ALTERNATIVE NAMES:
Aryl sulfotransferase 1A3/1A4; Sulfotransferase 1A3/1A4

ALTERNATIVE UPACC:
P0DMN0; B4DNV0; O95603; P50224; Q1ET66; Q6ZWJ5

BACKGROUND:
The enzyme Sulfotransferase 1A4, recognized alternatively as Aryl sulfotransferase 1A3/1A4, utilizes 3'-phospho-5'-adenylyl sulfate as a sulfonate donor to facilitate the sulfate conjugation of critical neurotransmitters and various drugs. This process is vital for the regulation of neurotransmitter levels and the metabolism of drugs, impacting their action and detoxification.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Sulfotransferase 1A4 unveils potential pathways for therapeutic intervention. Given its pivotal role in drug and neurotransmitter metabolism, targeting this enzyme could lead to innovative treatments for managing drug interactions and enhancing the therapeutic outcomes in neurological and psychiatric conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.